Christine Pascone Hudacek, PT | |
7501 Osler Dr Ste 301, Towson, MD 21204-7733 | |
(410) 337-1349 | |
Not Available |
Full Name | Christine Pascone Hudacek |
---|---|
Gender | Female |
Speciality | Physical Therapy |
Experience | 26 Years |
Location | 7501 Osler Dr Ste 301, Towson, Maryland |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1063079630 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225100000X | Physical Therapist | 19291 (Maryland) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
University Of Maryland St Joseph Rehabilitation Medicine Llc | 7012319148 | 12 |
News Archive
Regenerx Biopharmaceuticals Inc. has announced the results of its Phase II clinical trial evaluating the safety and wound-healing efficacy of RGN-137 for the treatment of patients with venous stasis ulcers.
BioRx, a specialty pharmacy company, has received limited distribution rights from Baxter International Inc. for a new drug, GLASSIA™ [Alpha 1-Proteinase Inhibitor (Human)], the first and only liquid, ready-to-use treatment for alpha-1 antitrypsin deficiency (AATD) in the United States. AATD is a genetic disorder that causes low levels of alpha 1-antitrypsin, resulting in emphysema. AATD is also referred to as "genetic" or "congenital" emphysema.
Actavis Group has announced that it has launched Ondansetron Tablets in the U.S. Actavis will market the product under an agreement with Natco Pharma Limited. Distribution of the product will commence immediately.
The Australian Therapeutic Goods Administration (TGA) has consulted today with the Chairs of its peak advisory committees, the Australian Adverse Drug Reactions Committee (ADRAC) and the Australian Drug Evaluation Committee (ADEC), about the latest research into the safety of the arthritis drug, Celebrex.
› Verified 8 days ago
Provider Name | University Of Maryland St Joseph Rehabilitation Medicine Llc |
---|---|
Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
Provider Identifiers | NPI Number: 1811578800 PECOS PAC ID: 7012319148 Enrollment ID: O20210713001232 |
News Archive
Regenerx Biopharmaceuticals Inc. has announced the results of its Phase II clinical trial evaluating the safety and wound-healing efficacy of RGN-137 for the treatment of patients with venous stasis ulcers.
BioRx, a specialty pharmacy company, has received limited distribution rights from Baxter International Inc. for a new drug, GLASSIA™ [Alpha 1-Proteinase Inhibitor (Human)], the first and only liquid, ready-to-use treatment for alpha-1 antitrypsin deficiency (AATD) in the United States. AATD is a genetic disorder that causes low levels of alpha 1-antitrypsin, resulting in emphysema. AATD is also referred to as "genetic" or "congenital" emphysema.
Actavis Group has announced that it has launched Ondansetron Tablets in the U.S. Actavis will market the product under an agreement with Natco Pharma Limited. Distribution of the product will commence immediately.
The Australian Therapeutic Goods Administration (TGA) has consulted today with the Chairs of its peak advisory committees, the Australian Adverse Drug Reactions Committee (ADRAC) and the Australian Drug Evaluation Committee (ADEC), about the latest research into the safety of the arthritis drug, Celebrex.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Christine Pascone Hudacek, PT 7501 Osler Dr Ste 301, Towson, MD 21204-7733 Ph: () - | Christine Pascone Hudacek, PT 7501 Osler Dr Ste 301, Towson, MD 21204-7733 Ph: (410) 337-1349 |
News Archive
Regenerx Biopharmaceuticals Inc. has announced the results of its Phase II clinical trial evaluating the safety and wound-healing efficacy of RGN-137 for the treatment of patients with venous stasis ulcers.
BioRx, a specialty pharmacy company, has received limited distribution rights from Baxter International Inc. for a new drug, GLASSIA™ [Alpha 1-Proteinase Inhibitor (Human)], the first and only liquid, ready-to-use treatment for alpha-1 antitrypsin deficiency (AATD) in the United States. AATD is a genetic disorder that causes low levels of alpha 1-antitrypsin, resulting in emphysema. AATD is also referred to as "genetic" or "congenital" emphysema.
Actavis Group has announced that it has launched Ondansetron Tablets in the U.S. Actavis will market the product under an agreement with Natco Pharma Limited. Distribution of the product will commence immediately.
The Australian Therapeutic Goods Administration (TGA) has consulted today with the Chairs of its peak advisory committees, the Australian Adverse Drug Reactions Committee (ADRAC) and the Australian Drug Evaluation Committee (ADEC), about the latest research into the safety of the arthritis drug, Celebrex.
› Verified 8 days ago
Joshua Kyle Welch, PT,DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 7402 York Rd, Suite 104, Towson, MD 21204 Phone: 410-260-3931 Fax: 410-560-0877 | |
Mr. Randall Hochberg, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 7401 Osler Dr, Suite 110, Towson, MD 21204 Phone: 410-296-8888 | |
Thomas Janicky, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 913 Southerly Rd, Unit 178, Towson, MD 21204 Phone: 732-600-5239 | |
Mr. Jeffrey Asbury, P.T. Physical Therapist Medicare: Medicare Enrolled Practice Location: 7401 Osler Dr, Towson, MD 21204 Phone: 410-296-8888 | |
Elisabeth Bryant, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 7401 Osler Dr, Suite 110, Towson, MD 21204 Phone: 410-296-8888 | |
Mr. Roger Hall, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 7401 Osler Dr, Suite 110, Towson, MD 21204 Phone: 410-296-8888 | |
Elizabeth A Harnois, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 7501 Osler Dr Ste 301, Towson, MD 21204 Phone: 410-337-1349 |